NDAINHALATIONSPRAY, METERED
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
4
Data completeness
4/8 — Partial
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPIRIVA RESPIMAT is a metered-dose inhalation spray formulation of tiotropium bromide, a long-acting anticholinergic bronchodilator used primarily for maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors in airway smooth muscle to promote bronchodilation and improve airflow. The RESPIMAT formulation delivers a slow-moving mist optimized for patient inhalation technique.
$924MPart D
Peak4.8 years to LOEPeak lifecycle with $924M in Part D spending signals a mature, high-volume franchise with established sales infrastructure but intensifying generic competition requiring defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Started Mar 2019
116,133 enrolled
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
Started Jul 2017
193 enrolled
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Started Jun 2015
359 enrolled
Asthma
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Started Jun 2008
1,280 enrolled
Pulmonary Disease, Chronic Obstructive
Why This Matters for Your Career
Worked on SPIRIVA RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.